eFFECTOR Therapeutics, Inc. (EFTR) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswereFFECTOR Therapeutics, Inc. (EFTR) trades at $0.0002. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing selective translation regulator inhibitors for cancer treatment. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for EFTR: EFTR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
eFFECTOR Therapeutics, Inc. (EFTR) Healthcare & Pipeline Overview
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in selective translation regulator inhibitors for cancer. Its lead product candidate, Tomivosertib, targets metastatic non-small cell lung cancer, while Zotatifin addresses solid tumors. The company operates in the competitive biotechnology sector, seeking to advance novel cancer therapies.
What Is the Investment Thesis for EFTR?
eFFECTOR Therapeutics presents a high-risk, high-reward investment opportunity characteristic of early-stage biopharmaceutical companies. The company's value hinges on the successful clinical development and potential regulatory approval of its lead product candidates, Tomivosertib and Zotatifin. Positive Phase 2b trial results for Tomivosertib in metastatic NSCLC could serve as a significant catalyst, driving investor interest and potentially leading to partnerships or acquisition offers. Similarly, advancement of Zotatifin through Phase 2 trials for solid tumors would bolster the company's pipeline and valuation. However, the company's reliance on a limited number of drug candidates and the inherent uncertainties of clinical trials pose substantial risks. As of 2026, the company's market capitalization is $0.00B, reflecting the speculative nature of its valuation.
Based on FMP financials and quantitative analysis
EFTR Key Highlights
Lead product candidate Tomivosertib is in Phase 2b clinical trial for metastatic non-small cell lung cancer.
- Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), is in Phase 2 clinical trial to treat patients with solid tumors.
- Collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E.
- The company was founded in 2012, indicating a relatively young company in the biotech space.
- The company has 14 employees, reflecting its status as a small, clinical-stage biopharmaceutical company.
Who Are EFTR's Competitors?
EFTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $37.82 | -2.70% | $167B | 87 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $520.66 | -2.94% | $132B | 90 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $923.34 | -2.35% | $95.5B | 95 5-pillar |
| ARGX argenx SE | $925.70 | -1.73% | $58.2B | 96 5-pillar |
| RPRX Royalty Pharma plc | $67.72 | -1.38% | $38.9B | 73 5-pillar |
| GMAB Genmab A/S | $51.35 | +0.75% | $31.7B | 72 5-pillar |
| UTHR United Therapeutics Corporation | $559.10 | -3.16% | $23.8B | 97 5-pillar |
| INCY Incyte Corporation | $114.63 | -1.07% | $23.4B | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EFTR's Key Strengths?
Novel approach to cancer treatment through selective translation regulation.
- Two drug candidates in Phase 2 clinical trials.
- Collaboration with Pfizer Inc.
- Experienced management team with expertise in drug development.
What Are EFTR's Weaknesses?
Limited financial resources as a small, clinical-stage company.
- Reliance on a small number of drug candidates.
- High risk of clinical trial failure.
- OTC market listing may limit access to capital.
What Are the Key Risks for EFTR?
Financial-distress signal — its Altman Z-Score of -13.56 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Tomivosertib or Zotatifin.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies.
- Limited financial resources and dependence on external funding.
- OTC market listing and associated risks.
What Are EFTR's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in selective translation regulation.
- Clinical trial data demonstrating efficacy and safety.
- Strategic collaborations with established pharmaceutical companies.
- First-mover advantage in targeting specific translation regulators.
What Does EFTR Do?
eFFECTOR Therapeutics, Inc., founded in 2012 and headquartered in Solana Beach, California, is a clinical-stage biopharmaceutical company dedicated to developing selective translation regulator inhibitors for cancer treatment. The company's primary focus is on modulating key pathways involved in cancer cell growth and survival through targeted therapies. Their lead product candidate, Tomivosertib, is an oral small-molecule inhibitor of MNK (MAPK-integrating kinase) currently in a Phase 2b clinical trial for patients with metastatic non-small cell lung cancer (NSCLC). Tomivosertib aims to disrupt cancer cell proliferation by targeting MNK, a key regulator of mRNA translation. In addition to Tomivosertib, eFFECTOR Therapeutics is developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4A), a crucial protein involved in the initiation of protein synthesis. Zotatifin is currently in a Phase 2 clinical trial for the treatment of patients with solid tumors. By inhibiting eIF4A, Zotatifin aims to selectively block the translation of oncogenic mRNAs, thereby suppressing tumor growth. eFFECTOR Therapeutics also has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E, further expanding its portfolio of translation regulator inhibitors. The company's strategic focus on selective translation regulation positions it within the innovative edge of cancer therapeutics, aiming to provide novel treatment options for patients with significant unmet medical needs.
What Products and Services Does EFTR Offer?
- Develop selective translation regulator inhibitors for cancer treatment.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Focus on modulating key pathways involved in cancer cell growth and survival.
- Target metastatic non-small cell lung cancer with Tomivosertib.
- Develop Zotatifin for the treatment of patients with solid tumors.
- Collaborate with Pfizer Inc. to develop inhibitors of eIF4E.
How Does EFTR Make Money?
- Develop and patent novel therapeutic candidates.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Potentially commercialize drugs directly or through partnerships.
- Generate revenue through drug sales, licensing agreements, or collaborations.
What Industry Does EFTR Operate In?
eFFECTOR Therapeutics operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and substantial financial investments. The oncology therapeutics market is a significant segment within the biotechnology industry, driven by the increasing prevalence of cancer and the demand for more effective and targeted treatments. eFFECTOR's focus on selective translation regulator inhibitors aligns with the industry trend toward precision medicine and personalized cancer therapies. Competitors include companies developing similar targeted therapies, as well as established pharmaceutical giants with extensive oncology portfolios. The success of eFFECTOR Therapeutics depends on its ability to differentiate its products, navigate the complex regulatory landscape, and secure strategic partnerships.
Who Are EFTR's Key Customers?
- Patients with cancer, specifically non-small cell lung cancer and solid tumors.
- Healthcare providers who prescribe and administer cancer treatments.
- Pharmaceutical companies seeking to acquire or license novel cancer therapies.
- Research institutions and collaborators involved in drug development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 8 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
eFFECTOR Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.56 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
eFFECTOR Therapeutics, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 3.2% below estimates on average.
Forward Outlook
Wall Street analysts project eFFECTOR Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-21.00.
Company Profile
eFFECTOR Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Solana Beach, US. EFTR has traded publicly since 2021.
EFTR Latest News
No recent news available for EFTR.
EFTR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EFTR.
Price Targets
Wall Street price target analysis for EFTR.
EFTR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EFTR; grades run from A+ (80-100) to F (below 30).
Leadership: Davide Ruggero
CEO
Davide Ruggero is the CEO of eFFECTOR Therapeutics, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has a proven track record in leading and managing research and development programs, as well as driving strategic initiatives. Ruggero's expertise spans various aspects of drug discovery, clinical development, and commercialization. He is responsible for overseeing the overall direction and operations of eFFECTOR Therapeutics.
Track Record: Under Davide Ruggero's leadership, eFFECTOR Therapeutics has advanced its lead product candidates, Tomivosertib and Zotatifin, into Phase 2 clinical trials. He has also secured a collaboration agreement with Pfizer Inc., demonstrating his ability to forge strategic partnerships. Ruggero has focused on building a strong team and fostering a culture of innovation within the company.
EFTR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that eFFECTOR Therapeutics may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume leads to higher price volatility.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's capitalization structure and ownership.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Existence of a collaboration agreement with Pfizer Inc.
- Advancement of drug candidates into Phase 2 clinical trials.
- Experienced management team with expertise in drug development.
- Focus on a specific therapeutic area (cancer).
- Company was founded in 2012, indicating several years of operation.
eFFECTOR Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does eFFECTOR Therapeutics, Inc. do?
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate, Tomivosertib, is in Phase 2b clinical trial for metastatic non-small cell lung cancer.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited or unreliable.